Search

Viking Therapeutics Inc

Avatud

SektorTervishoid

34.42 3.96

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

32.61

Max

34.95

Põhinäitajad

By Trading Economics

Sissetulek

30M

-128M

Aktsiakasum

-1.1

Töötajad

65

EBITDA

30M

-128M

Soovitused

By TipRanks

Soovitused

Tugev "osta" hinnang

12 kuu keskmine prognoos

+170.84% upside

Dividendid

By Acuity

Järgmine tulemuste avaldamine

21. okt 2026

Turustatistika

By TradingEconomics

Turukapital

-126M

3.9B

Eelmine avamishind

30.46

Eelmine sulgemishind

34.42

Uudiste sentiment

By Acuity

50%

50%

150 / 340 Pingereas Healthcare

Viking Therapeutics Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

24. aug 2026, 19:56 UTC

Social Media

Viking Therapeutics Inc shares are lower today, continuing a decline since Friday. Social media discussions highlight anticipation for upcoming data before Labor Day.

20. aug 2026, 20:06 UTC

Macro Event
Social Media

Viking Therapeutics Inc shares are lower, impacted by labor market data and heightened volatility, despite social media discussions suggesting potential recovery from a clinical trial.

19. aug 2026, 23:16 UTC

Viking Therapeutics Inc shares are higher in after-market hours, reflecting a gain since Wednesday's close and remaining above the 20-day moving average.

18. aug 2026, 19:16 UTC

Viking Therapeutics Inc shares are lower today, with no specific news driving the decline amid rising U.S. Treasury yields affecting the biotechnology sector.

17. aug 2026, 23:06 UTC

Viking Therapeutics Inc shares are higher in after-market trading, reflecting unusual strength. No specific company news was identified to explain the price movement.

14. aug 2026, 23:06 UTC

Viking Therapeutics Inc shares are lower in after-market hours, trading at the lower end of their one-month range and below the 20-day moving average.

13. aug 2026, 23:16 UTC

Viking Therapeutics Inc shares are lower in after-market trading, with no specific news identified to explain the decline. The stock is near its one-month low.

12. aug 2026, 23:26 UTC

Viking Therapeutics Inc is trading lower in after-market hours, reflecting notable weakness with no specific news identified to explain the decline.

7. aug 2026, 19:36 UTC

Social Media

Viking Therapeutics is rising amid broader market gains and anticipation of VK2809 trial results, with analysts noting potential for improved market position.

6. aug 2026, 23:16 UTC

Social Media

Viking Therapeutics Inc gains in after-market hours amid discussions on pharmacokinetic modeling and anticipated VKTX maintenance readout results.

5. aug 2026, 22:51 UTC

Viking Therapeutics Inc. shares are lower in after-market hours, continuing a decline from Wednesday's close amid unusual volatility and trading below the 20-day moving average.

4. aug 2026, 23:02 UTC

Social Media

Viking Therapeutics Inc shares are lower in after-market hours amid routine trading. The stock remains below its 20-day moving average.

3. aug 2026, 23:06 UTC

Viking Therapeutics shares are higher in after-market trading, reflecting positive sentiment from stronger-than-expected manufacturing PMI data indicating sector growth.

31. juuli 2026, 23:51 UTC

Viking Therapeutics Inc is higher in after-market trading, recovering from earlier session lows after four consecutive declines. The stock remains below its 20-day moving average.

30. juuli 2026, 23:56 UTC

News

Viking Therapeutics Inc. shows a modest gain in after-market hours amid a wave of biopharmaceutical mergers, including Vertex's $10 billion acquisition of Crinetics.

29. juuli 2026, 23:21 UTC

Social Media
News

Viking Therapeutics reported a Q2 loss of $1.10 per share, better than expected. The company highlighted progress in its obesity treatment pipeline.

28. juuli 2026, 23:11 UTC

News

Viking Therapeutics shares are lower in after-market hours amid ongoing challenges and a significant decline over the past two years. Analysts maintain a bullish outlook.

27. juuli 2026, 23:56 UTC

Viking Therapeutics Inc shares are lower in after-market hours, reflecting a lack of specific news and remaining below the 20-day moving average.

25. juuli 2026, 00:01 UTC

Viking Therapeutics Inc shares are lower in after-market trading, continuing a trend of four consecutive sessions finishing down. No specific news was identified.

24. juuli 2026, 21:01 UTC

Viking Therapeutics Inc. is higher in after-market trading, reversing recent losses despite no specific news driving the price movement.

23. juuli 2026, 23:46 UTC

Event

Viking Therapeutics shares are higher in after-market trading ahead of Q2 earnings, with estimated EPS of -$1.21, up from -$0.58.

22. juuli 2026, 23:36 UTC

Viking Therapeutics Inc. shares showed little change during after-market hours, trading within a narrow range and settling near unchanged levels.

Võrdlus sarnastega

Hinnamuutus

Viking Therapeutics Inc Prognoos

Hinnasiht

By TipRanks

170.84% tõus

12 kuu keskmine prognoos

Keskmine 90 USD  170.84%

Kõrge 114 USD

Madal 65 USD

Põhineb 15 Wall Streeti analüütiku instrumendi Viking Therapeutics Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

15 ratings

15

Osta

0

Hoia

0

Müü

Sentiment

By Acuity

150 / 340 Pingereas Tervishoid

Uudiste sentiment

Neutral

Volatiilsus

Alla keskmise

Uudismaht (RCV)

Alla keskmise

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest Viking Therapeutics Inc

Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; VK2735, a novel dual agonist of the glucagon-like peptide, which is in Phase 1 SAD/MAD clinical trial, and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.
help-icon Live chat